ProCE Banner Activity


APPlexus Hot Topics 2024: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL


On-demand webcast of expert faculty presentation and case discussion on treating patients with CLL and MCL with non-covalent BTK inhibitors, as presented at CCO and PCE’s APPlexus Hot Topics 2024.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 05, 2024

Expiration: June 03, 2025



Sandra E. Kurtin

Sandra E. Kurtin, PhD, ANP-BC, FAPO

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona
Tucson, Arizona

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC


Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This program is intended for NPs, PAs, and other healthcare professionals caring for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.

Program Learning Goal

To improve the knowledge, confidence, and skills of NPs/PAs who care for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL on the latest updates in evidence-based medicine using noncovalent BTK inhibitors to improve health equity, ultimately improving clinical outcomes for their patients.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Describe to patients the differences between covalent and noncovalent BTKi in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice

  • Evaluate the available clinical evidence and guideline recommendations on noncovalent BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL

  • Manage adverse events associated with noncovalent BTKi-based therapies considering safety profiles unique to each agent and regimen

  • Identify patients with R/R MCL and R/R CLL/SLL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations


PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Sandra E. Kurtin, PhD, ANP-BC, FAPO

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona
Tucson, Arizona

Sandra E. Kurtin, PhD, ANP-BC, FAPO: consultant/advisor/speaker: AbbVie, Agios, Amgen, GlaxoSmithKline.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 05, 2024, through June 03, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement


In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 03, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.